MarketPulse

pan-PPAR agonist

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva Files Annual Reports With €230.9M Cash Pile Amid MASH Drug Development

Inventiva filed 2025 regulatory documents showing €230.9M cash reserves and €4.5M revenues while advancing lanifibranor in Phase 3 MASH trials.
IVAPhase 3 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Inventiva to Report 2025 Results as MASH Drug Candidate Advances

Inventiva will release 2025 financial results March 30, 2026, while advancing lanifibranor in Phase 3 MASH trials.
IVAPhase 3 clinical trialfinancial results